In mice with early-onset disc degeneration, treatment with dasatinib and quercetin suppressed senescence-associated signalling and preserved disc cell phenotype.

Higher levels of air pollution are associated with increased disease activity and flare risk in patients with rheumatoid arthritis, according to findings from a prospective cohort study.

Lymph node architecture sequesters B cells away from effector cells, limiting antibody-mediated depletion and highlighting tissue remodelling as a strategy to improve therapeutic responses.

In two phase III trials, secukinumab improved rates of sustained remission and reduced glucocorticoid use in polymyalgia rheumatica but did not improve outcomes in giant cell arteritis.

Findings show that lytic cell death releases TRIM21, promoting immune complex uptake by macrophages and autoimmune inflammation in Sjögren disease.

A new study reveals that the Epstein–Barr virus can reprogramme autoreactive B cells into pathogenic antigen-presenting cells in systemic lupus erythematosus, providing a mechanistic link between infection and autoimmunity.

In the phase III POETYK PsA-2 trial, deucravacitinib improved outcomes across multiple domains of psoriatic arthritis and had a favourable safety profile.

A multi-omics study reveals that lactylation of the antioxidant enzyme SOD1 promotes oxidative stress and intervertibral disc degeneration. Blocking this modification, genetically or with a targeted inhibitor, reduced oxidative damage and alleviated disc degeneration in rat models of IVDD.

Comparing dermatomyositis with cutaneous lupus erythematosus, single-cell analysis identifies monocyte-mediated endothelial injury as a dermatomyositis-specific feature and highlights JAK1 inhibition as a potential therapeutic approach.

Intracellular succinate promotes inflammatory macrophage responses through mitochondrial GPR91 signalling, linking metabolic dysregulation to macrophage-driven inflammation in rheumatoid arthritis.

Biallelic loss-of-function mutations in PLD4, as identified in five patients with SLE, lead to Toll-like receptor-driven hyperactivation of type I interferon, immune cell expansion and autoimmunity.

A new population-based study suggests that sodium–glucose cotransporter-2 (SGLT2) inhibitors — originally developed for glycaemic control — reduce the risk of autoimmune rheumatic diseases.

A new study uncovers how UBA1 mutations in VEXAS syndrome simultaneously promote myeloid inflammatory cell death and skew haematopoietic stem cells towards a myeloid lineage.

Researchers have identified a mechanistic link between SARS-CoV-2 infection and multisystem inflammatory syndrome in children, providing evidence for the involvement of molecular mimicry.

Type 2 innate lymphoid cells protect against kidney inflammation in lupus nephritis, and enhancing their adhesion via integrin alpha 4 beta 7 upregulation, particularly through IL-33 treatment, could be a promising therapeutic approach.

Methotrexate reduces pain and stiffness in hand osteoarthritis with synovitis, according to the results of a new randomized controlled trial.

New findings provide insight into the natural history of subclinical synovitis, a reported predictor of the development of rheumatoid arthritis, and identify various factors associated with its reversal.

New findings identify HSP60 and other synovial stromal-derived autoantigens as targets for pathogenic autoantibodies, exacerbating arthritis and serving as potential biomarkers.

Ribonucleoprotein complexes containing Xist, a long non-coding RNA involved in X chromosome inactivation, are immunogenic and promote autoimmune responses.

New findings suggest that targeting the DAMP protein S100A4 could mitigate both inflammatory and fibrotic pathways in systemic sclerosis.